Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-BD: Empagliflozin for Bipolar Depression with Insulin Resistance
NCT07472920Not yet recruiting
- Sponsor
- Universidade de São Paulo
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin in bipolar disorder (BD), sponsored by Universidade de São Paulo. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 12 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT07472920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472920.